:
MCDC@ati.org
 

Accelerating DoD’s Fielding of Prototypes for Medical Countermeasures

Coronavirus COVID-19 Department of the Army Memo to Small Businesses CORONAVIRUS INFORMATION AAE Memo to Defense Industrial Base CISA Guidance on Essential Critical Infrastructure Workers NEW OPPORTUNITIES MCDC2011: COVID-19 Pandemic Vaccine Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing
0
Current Members
0
Awards
0
Funded to Date

Non-Traditional Members

Hands Icon

PREVENT

Prophylaxis, pretreatment, and post-exposure prophylaxis

Hospital Icon

DIAGNOSE

Systems and devices to identify CBRN agents and assist in making medical decisions

Treat Icon

TREAT

Therapeutics for post-exposure and post-symptomatic

The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense’s (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.

WHO CAN JOIN

Companies that are part of the US Industrial base, as well as new and emerging non-traditional defense contractors, are encouraged to join the MCDC and participate in Federally-funded R&D projects.

  • Traditional Contractors
  • Non-Traditionals (Companies that don’t typically participate in Federal R&D)
  • Academia
  • Non-Profit/ Not-For-Profit Research Institutions
Learn How to Join

Led by

MCDC research and prototype work is executed by project teams from a broad-based industry/ academia collaboration.

Sponsored by

Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBRND) Logo

Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense

Managed by

ATI: Advanced Technology International

Collaboration Management Firm Advanced Technology International (ATI)